Neurothera Labs Inc. (TSXV:NTLX)

Neurothera Labs Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Revenue Revenue Growth	0.68	0.86	1.31
Revenue Growth	-47.93%	-34.46%	-
Gross Profit Gross Profit Growth	0.48	0.63	0.51
Operating Income Operating Income Growth	-3.85	-2.74	-2.81
Net Income Net Income Growth	-5.2	-4.12	-2.94
Earnings Per Share EPS Growth	-0.88	-0.86	-0.65
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	0.89	1.7	0.12
Total Debt Total Debt Growth	0.9	0.93	-
Net Cash (Debt) Net Cash Growth	-0.01	0.77	0.12
Net Cash Growth	-	555.56%	-
Net Cash Per Share Net Cash Per Share Growth	-0.00	0.16	0.03

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-1.62	-1.66	-1.69
Free Cash Flow Free Cash Flow Growth	-1.62	-1.66	-1.69
Free Cash Flow Growth	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Gross Margin	71.18%	73.72%	38.74%
Operating Margin	-565.44%	-319.74%	-214.78%
Pretax Margin	-795.29%	-507.48%	-316.00%
Profit Margin	-765.15%	-481.66%	-225.27%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Sep 10, 2026	Dec 31, 2025	Dec 31, 2024
PS Ratio	62.39	12.30	1.21

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 9, 2026

Data Sources Report a data error